Abcam, ab108734, Human Anti-Entamoeba histolytica IgG ELISA Kit

Size: 1 x 96Tests
Human Anti-Entamoeba histolytica IgG ELISA Kit is an indirect ELISA for the qualitative detection of IgG class antibodies against Entamoeba histolytica in human plasma and serum samples. - Colorimetric readout - 450 nm - Works on any standard plate reader - Easy results interpretation - Cut-off, positive and negative controls included
Key facts
Detection method:Colorimetric,
Sample types:Citrate plasma, Heparin Plasma, Serum,
Reacts with:Human,
Assay type:Indirect,
Assay Platform:Microplate

Product details:
Abcam's anti-Entamoeba histolytica IgG Human
in vitro
ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgG class antibodies against Entamoeba histolytica in Human serum and plasma.
A 96-well plate has been precoated with Entamoeba histolytica antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a Protein A peroxidase labelled anti-Human IgG conjugate is added to the wells, which binds to the immobilized Entamoeba histolytica-specific antibodies. TMB is then catalyzed by the Protein A to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Entamoeba histolytica IgG sample captured in plate.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Entamoeba histolytica IgG an antibody specific to the parasite Entamoeba histolytica plays a significant role in the immune response. Entamoeba histolytica is a protozoan parasite responsible for amoebiasis commonly known as amoebic dysentery. The IgG form of antibodies is an important marker used in the detection and study of this parasite. The molecular mass of Entamoeba histolytica IgG remains consistent with typical IgG antibodies approximately 150 kDa. This antibody gets expressed in response to infection by Entamoeba histolytica a condition that leads to an inflammatory response primarily observed in the intestinal and liver tissues.
Biological function summary
Entamoeba histolytica IgG contributes to immune defense by identifying and marking Entamoeba histolytica cells for destruction by other immune cells. It does not form part of a larger protein complex but instead operates through its specific binding capacity. Upon binding to antigens presented by Entamoeba histolytica this IgG type facilitates the process of phagocytosis by engaging phagocytic cells such as macrophages and neutrophils. This immune response serves as a primary line of defense to control the infection and limit the spread of the parasite within the host's body.
Pathways
Entamoeba histolytica IgG gets engaged in the humoral immune response which is integral to the adaptive immune system. This process involves pathways like the complement system pathway wherein the binding of IgG to the parasite antigens activates a cascade that leads to opsonization complement fixation and eventual lysis of the parasitic cells. Additionally the antibody engages in antibody-dependent cellular cytotoxicity (ADCC) pathways which involve recruiting natural killer cells to target the infected cells thereby reducing parasite survival and proliferation.
Entamoeba histolytica IgG is closely linked to intestinal amoebiasis and amoebic liver abscess. The presence of this IgG in blood serology tests helps diagnose these conditions early. During the pathogenesis of these diseases Entamoeba histolytica interacts with other host proteins like complement proteins and those involved in the liver's inflammatory response such as cytokines like TNF-alpha and IL-1beta. Increased levels of Entamoeba histolytica IgG suggest ongoing infection or exposure to the pathogen aiding clinicians in disease management.